Biotech Values

[SimpleTruths]

The new action by Amphastar relating to Dr. Woodcock adds to the circumstantial evidence that Amphastar’s ANDA is unlikely to be approved.

Sadly, it also adds to a large body of evidence that many long-time FDA employees wouldn't see the appearance of conflict of interest if it co-authored a journal article with them. They do the rest of the Agency a grave disservice in the public arena.

ST